Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 3, 2015, Pages 629-638

  D'Angelo, Sandra P ^a,b   Mahoney, Michelle R ^c   Van Tine, Brian A ^d   Adkins, Douglas R ^d   Perdekamp, Maria T Grosse ^e   Condy, Mercedes M ^a   Luke, Jason J ^f   Hartley, Eliza Woodward ^a   Antonescu, Cristina R ^a   Tap, William D ^a,b   Schwartz, Gary K ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Carle Cancer Center   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Department of Medicine   (United States)

Author keywords

Angiopoietin system; Angiosarcoma; Trebananib

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; MYC PROTEIN; TREBANANIB; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN;

ADULT; AGED; ANEMIA; ANGIOSARCOMA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERKALEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LUNG EDEMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMANGIOSARCOMA; MIDDLE AGED; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; DISEASE-FREE SURVIVAL; FEMALE; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925497823     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2689-8     Document Type: Article

References (32)

1. Young RJ, Brown NJ, Reed MW et al (2010) Angiosarcoma. Lancet Oncol 11:983-991
2. Fury MG, Antonescu CR, Van Zee KJ et al (2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11:241-247
3. Mark RJ, Poen JC, Tran LM et al (1996) Angiosarcoma: a report of 67 patients and a review of the literature. Cancer 77:2400-2406
4. Rouhani P, Fletcher CD, Devesa SS, Toro JR (2008) Cutaneous soft tissue sarcoma incidence patterns in the US: an analysis of 12,114 cases. Cancer 113:616-627
5. Agulnik M, Yarber JL, Okuno SH et al (2013) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24:257-263
6. Italiano A, Cioffi A, Penel N et al (2012) Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118:3330-3336
7. Maki RG, D'Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133-3140
8. Penel N, Bui BN, Bay JO et al (2008) Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 26:5269-5274
9. Ray-Coquard I, Italiano A, Bompas E et al (2012) Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17:260-266
10. Agulnik M, Yarber JL, Okuno SH, Von Mehren M, Jovanovic B, Brockstein B, Benjamin RS, Evens AM (2009) An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 27
11. Hashizume H, Falcon BL, Kuroda T et al (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70:2213-2223
12. Amo Y, Masuzawa M, Hamada Y, Katsuoka K (2004) Observations on angiopoietin 2 in patients with angiosarcoma. Br J Dermatol 150:1028-1029
13. Brown LF, Dezube BJ, Tognazzi K et al (2000) Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156:2179-2183
14. Investigator's Brochure (2011) AMG 386, 7th edn. Amgen, Thousand Oaks
15. Coxon A, Bready J, Min H et al (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9:2641-2651
16. Simon R (1989) Optimal two-stage designs for phase ii clinical trials. Elsevier, New York
17. Kaplan EMP (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53(53):457-481
18. George S, Merriam P, Maki RG et al (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:3154-3160
19. Lahat G, Dhuka AR, Hallevi H et al (2010) Angiosarcoma: clinical and molecular insights. Ann Surg 251:1098-1106
20. Amo Y, Masuzawa M, Hamada Y, Katsuoka K (2001) Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS). Arch Dermatol Res 293:296-301
21. Fayette J, Martin E, Piperno-Neumann S et al (2007) Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 18:2030-2036
22. Dumont DJ, Yamaguchi TP, Conlon RA et al (1992) tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:1471-1480
23. Partanen J, Armstrong E, Makela TP et al (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 12:1698-1707
24. Shim WS, Ho IA, Wong PE (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5:655-665
25. Tanaka F, Ishikawa S, Yanagihara K et al (2002) Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124-7129
26. Sallinen H, Heikura T, Laidinen S et al (2010) Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer 20:1498-1505
27. Bach F, Uddin FJ, Burke D (2007) Angiopoietins in malignancy. Eur J Surg Oncol 33:7-15
28. Cao Y, Sonveaux P, Liu S et al (2007) Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 67:3835-3844
29. Hawighorst T, Skobe M, Streit M et al (2002) Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381-1392
30. Stoeltzing O, Ahmad SA, Liu W et al (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63:3370-3377
31. Tian S, Hayes AJ, Metheny-Barlow LJ, Li LY (2002) Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer 86:645-651
32. van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886